Research programme: monoclonal antibody therapeutics - Active Motif/Hisun BioRay
Latest Information Update: 28 May 2024
At a glance
- Originator Active Motif
- Developer Active Motif; Hisun BioRay
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections in China (Parenteral)
- 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
- 15 Apr 2020 Antibody therapeutics licensed to Hisun BioRay for COVID-2019 infections